Cofactor Genomics

Cofactor Genomics

A company using RNA to diagnose disease and to develop biomarkers that predict treatment outcomes. Cofactor is founded by Jarret Glasscock.

Cofactor Genomics uses Predictive Immune Modeling for the development of faster, more cost effective and successful clinical trials. Predictive Immune Modeling acquires a picture of immune response at the tumor and represents the patient’s immune response, their response to therapy and potentially the prognosis, in a multi-faceted way. Multidimentional biomarkers help predict responses to drugs and therapy.

Cofactor Genomics analyzes the presence, absence of RNA and dynamic levels of gene expression. Genes that are expressed are active and transcribe RNA. Gene expression levels can be influenced by factors including the state of disease, environmental effects and therapy. Cofactor has built Health Expression Models, which are gene expression profiles for key immune cell types.

In February 2018, Cofactor announced a $100,000 grant program which will reward innovations that use the Cofactor ImmunoPrism Assay. CEO and founder Jarret Glasscock explains that the grant is designed to inspire researchers to take different approaches with the aim of achieving highly predictive biomarkers that can predict whether an immunotherapy will work with a specific patient or cancer type.

Products and services

Solid tumor samples can be sent to Cofactor for analysis using the ImmunoPrism Assay and individual samples are compared to the Health Expression Models database which represents key immune cell types. An ImmunoPrism Report is generated for each patient. When clinical outcome data is available for patient cohorts, their Predictive Immune Modeling platform will generate a multidimensional biomarker. The platform uses machine-learning.

Cofactor provides a range of RNA sequencing services.

The ImmunoPrism (formerly called Paragon) assay completed validation and certification by the College of American Pathologists (CAP) in 2018. Cofactor’s ImmunoPrism Immune Profiling Kit was launched in 2018, which gives laboratories access to the same kit the company uses for sample preparation, sequencing and analysis of tumor samples.

Timeline

October 30, 2018
ImmunoPrism™ Immune Profiling Kit launched
October 2, 2018
College of American Pathologists certifies Tumor Immune-Profiling Assay, ImmunoPrismTM

September 2017
Cofactor Genomics raises a $18,000,000 series A round from Menlo Ventures, Stanford University, iSelect Fund, Refactor Capital, Silicon Valley Bank, Y Combinator, DCVC Bio, Argonautic Ventures, Ascension Ventures and Wilson Sonsini Goodrich & Rosati.
June 2017
Cofactor Genomics raises a $18,000,000 series A round from Menlo Ventures, Fifty Years, iSelect Fund, Refactor Capital and Data Collective.
August 2015
Cofactor Genomics raises a $120,000 seed round from Y Combinator.
July 2015
Cofactor Genomics raises a $2,600,000 seed round from Paul Buchheit, TenOneTen Ventures, David Lee, Eric Kwan, BioGenerator, DCVC Bio, Jude Gomila, 7percent Ventures, AME Cloud Ventures and Greg Castle.
January 2008
Cofactor Genomics raises a $200,000 angel round.

Funding rounds

Funding round
Funding type
Funding round amount (USD)
Funding round date
Investment
Cofactor Genomics Seed round, July 2015
2,600,000
July 2015
5 Results
Results per page:
Page 1 of 1

People

Name
Role
LinkedIn

Dave Messina

Founder

David Lee

Investor

dev null

Employee

Greg Castle

Investor

Jarret Glasscock

Founder

Jeff Chung

Investor

Joey Babbitt

Employee

John Kuelper

Board member

Jon Armstrong

Founder

Jude Gomila

Investor

Paul Buchheit

Investor

Stefano Bernardi

Investor

Zal Bilimoria

Investor

Further reading

Title
Author
Link
Type
Date

Documentaries, videos and podcasts

Title
Date
Link

Companies

Company
CEO
Location
Products/Services

References

Golden logo
Text is available under the Creative Commons Attribution-ShareAlike 4.0; additional terms apply. By using this site, you agree to our Terms & Conditions.